Abstract:Extraintestinal manifestations (EIM) of inflammatory bowel disease (IBD) were first described in 1976. 1 The anti-tumour necrosis factors agents signed the emergence of potent systemic treatment in IBD, allowing us to look beyond the gut and effectively treat these manifestations along with the luminal disease. 2 In the early 2000s, a landmark positive randomised controlled trial was conducted with infliximab for pyoderma gangrenosum. 3 A few years later, with the vedolizumab approval, the concept of gut-selec… Show more
“…We agree with the EXTRA authors regarding the complimentary but distinct goals of our two initiatives 2,3 . The EXTRA consensus was designed specifically to identify EIM endpoints for use in clinical trials 1 . The findings of their panel, including the need for subspecialty involvement and dedicated follow‐up every 4–12 weeks depending on the EIM in question, is consistent with this objective 2 .…”
supporting
confidence: 53%
“…We would like to thank Dr. Guillo and colleagues for their thoughtful editorial, 1 for highlighting our manuscript and for their contributions to the literature surrounding extra‐intestinal manifestations (EIMs) in inflammatory bowel disease (IBD). EIMs represent a critically unmet need, with limited data to guide management.…”
LINKED CONTENT
This article is linked to Falloon et al papers. To view these articles, visit https://doi.org/10.1111/apt.16853 and https://doi.org/10.1111/apt.16882
“…We agree with the EXTRA authors regarding the complimentary but distinct goals of our two initiatives 2,3 . The EXTRA consensus was designed specifically to identify EIM endpoints for use in clinical trials 1 . The findings of their panel, including the need for subspecialty involvement and dedicated follow‐up every 4–12 weeks depending on the EIM in question, is consistent with this objective 2 .…”
supporting
confidence: 53%
“…We would like to thank Dr. Guillo and colleagues for their thoughtful editorial, 1 for highlighting our manuscript and for their contributions to the literature surrounding extra‐intestinal manifestations (EIMs) in inflammatory bowel disease (IBD). EIMs represent a critically unmet need, with limited data to guide management.…”
LINKED CONTENT
This article is linked to Falloon et al papers. To view these articles, visit https://doi.org/10.1111/apt.16853 and https://doi.org/10.1111/apt.16882
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.